Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
18:55:00 02/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 74.86 EUR | +0.43% |
|
-3.68% | +19.97% |
| 10-02 | Eurofins Completes Sale of MET Labs Business | MT |
| 10-01 | UL Solutions Completes Acquisition of Eurofins' Electrical, Electronics Business | MT |
| Market Cap | 13B 14.63B 12.13B 11.06B 20.85B 1,406B 21.04B 147B 56.88B 719B 54.92B 53.72B 2,307B | P/E 2026 * |
25x | P/E 2027 * | 19.7x |
|---|---|---|---|---|---|
| Enterprise Value | 16.36B 18.41B 15.27B 13.92B 26.25B 1,770B 26.5B 185B 71.61B 905B 69.14B 67.64B 2,904B | EV / Sales 2026 * |
2.17x | EV / Sales 2027 * | 2.02x |
| Free-Float |
60.39% | Yield 2026 * |
1.07% | Yield 2027 * | 1.21% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
Tradegate
| ESF0 | Real-time | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
OTC Markets
| ERFSF | Delayed | |
|
Xetra
| ESF0 | Delayed | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
London S.E.
| 0MV5 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript: Eurofins Scientific SE
| 1 day | +0.43% | ||
| 1 week | -3.68% | ||
| Current month | -0.19% | ||
| 1 month | +4.61% | ||
| 3 months | +9.35% | ||
| 6 months | +15.06% | ||
| Current year | +19.97% |
| 1 week | 73.3 |  | 78.92 |
| 1 month | 68.38 | | 79.22 |
| Current year | 56.84 | | 79.22 |
| 1 year | 54.86 | | 79.22 |
| 3 years | 39.47 | | 79.22 |
| 5 years | 39.47 | | 118.12 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 01/01/1987 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 01/01/2015 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 01/01/1987 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 01/01/2015 |
Valérie Hanote
BRD | Director/Board Member | 60 | 01/01/1990 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/27/26 A | Buy | 700 | 0.0004% | |||
| 4/19/26 A | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 4/19/26 A | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.43% | -3.68% | +18.71% | +39.93% | 14.57B | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.41B | |
| -3.11% | -3.53% | +21.92% | +74.60% | 59.26B | |
| +0.89% | -0.77% | +5.80% | +32.89% | 47.14B | |
| -0.96% | -4.50% | +26.36% | +33.18% | 42.91B | |
| +0.36% | +0.81% | +352.17% | +689.61% | 44.13B | |
| -0.20% | -0.77% | +3.74% | +100.60% | 40.79B | |
| -0.54% | +2.93% | +9.50% | +50.41% | 30.77B | |
| -2.68% | +5.11% | +33.11% | +19.50% | 29.31B | |
| +2.33% | -5.69% | -27.28% | +338.00% | 23.71B | |
| Average | +0.07% | -1.03% | +49.34% | +147.29% | 40.7B | |
| Weighted average by Cap. | +0.25% | -1.05% | +56.41% | +146.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.54B 8.48B 7.03B 6.41B 12.09B 815B 12.2B 85.13B 32.99B 417B 31.85B 31.16B 1,338B | 7.94B 8.94B 7.41B 6.76B 12.75B 860B 12.86B 89.73B 34.77B 439B 33.57B 32.84B 1,410B |
| Net income | 531M 598M 496M 452M 852M 57.44B 860M 6B 2.32B 29.37B 2.24B 2.19B 94.24B | 660M 742M 616M 561M 1.06B 71.38B 1.07B 7.45B 2.89B 36.49B 2.79B 2.73B 117B |
| Net Debt | 3.37B 3.79B 3.14B 2.86B 5.4B 364B 5.45B 38.02B 14.73B 186B 14.22B 13.91B 598B | 3.03B 3.41B 2.83B 2.58B 4.87B 328B 4.91B 34.27B 13.28B 168B 12.82B 12.54B 539B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/10/26 | €74.86 | +0.43% | 416,371 |
| 01/10/26 | €74.54 | -0.61% | 496,921 |
| 30/09/26 | €75.00 | -1.57% | 653,261 |
| 29/09/26 | €76.20 | -3.20% | 305,088 |
| 28/09/26 | €78.72 | +1.76% | 190,736 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
